NCT00104923 - Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

April 30, 2017

Study Completion Date

April 30, 2017

Conditions

Chronic Myeloproliferative DisordersLeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm

Interventions

DRUG

fenretinide

Current dose level as an IV continuous infusion via central line over 5 days. Cycle is repeated every 3 weeks for up to 6 cycles

Trial Locations (4)

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles

Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda

M. D. Anderson Cancer Center at University of Texas, Houston

Joe Arrington Cancer Research and Treatment Center, Lubbock

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

California Cancer Consortium

NETWORK